MIRM

Is ANAB a good stock to buy? We came across a bullish thesis on AnaptysBio, Inc. on TripleS Special Situations’s Substack.

Mirum Pharmaceuticals has delivered a very strong multi year share price run, and with the stock recently closing at US$85.56 the live question is whether that level can be explained by what the business is generating in sales today.

Mirum Pharmaceuticals (MIRM) is back on investors’ radar after new data from its PROGRESS trial showed that ATEBRIOZ reduced heterotopic ossification lesion volume and improved joint mobility in younger pediatric FOP patients.

Mirum Pharmaceuticals (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

FOSTER CITY, Calif., October 26, 2026--Mirum Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Patients Aged 6 to <12 Years with FOP

MIRM's Livmarli meets the phase III EXPAND study goal, improving cholestatic pruritus and reducing serum bile acids, with an FDA filing planned for 2027.

If given the FDA blessing, Livmarli could become indicated in the US for the treatment of ultra-rare liver diseases like biliary atresia.

Mirum Pharmaceuticals (NASDAQ:MIRM) said its Phase III EXPAND study of LIVMARLI, or maralixibat, met its primary endpoint and all prespecified secondary endpoints in pediatric patients with cholestatic pruritus associated with ultra-rare cholestatic liver…

Investing.com -- Mirum Pharmaceuticals Inc (NASDAQ:MIRM) shares advanced 2.9% in premarket trading after the rare disease specialist announced positive topline results from its Phase 3 EXPAND study evaluating LIVMARLI (maralixibat) in patients with ultra-rare…